Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis

被引：9

作者：

Nakayama, Yoichi ^{[1
]}

Nagata, Wataru ^{[2
]}

Takeuchi, Yoichi ^{[3
]}

Fukui, Sho ^{[4
]}

Fujita, Yuya ^{[5
]}

Hosokawa, Yohei ^{[6
]}

Ueno, Masanobu ^{[5
]}

Ono, Kumiko ^{[7
]}

Sumitomo, Shuji ^{[8
]}

Tabuchi, Yuya ^{[1
]}

Nakanishi, Yuichiro ^{[9
]}

Saito, Shuntaro ^{[10
]}

Ikeuchi, Hiroko ^{[11
]}

Kawamori, Kazutaka ^{[13
]}

Sofue, Hideaki ^{[9
]}

Doi, Goro ^{[14
]}

Minami, Runa ^{[15
]}

Hirota, Tomoya ^{[16
]}

Minegishi, Kaoru ^{[17
]}

Maeshima, Keisuke ^{[18
]}

Motoyama, Ryo ^{[19
]}

Nakamura, Shohei ^{[19
]}

Suzuki, Shotaro ^{[20
]}

Nishioka, Norihiro ^{[11
,12
]}

Wada, Takuma Tsuzuki ^{[21
]}

Onishi, Akira ^{[22
]}

Nishimura, Kenichi ^{[23
]}

Watanabe, Ryu ^{[24
]}

Yanai, Ryo ^{[13
]}

Kida, Takashi ^{[9
]}

Nishiwaki, Hiroki ^{[12
,25
]}

Yajima, Nobuyuki ^{[13
]}

Kaneko, Yuko ^{[10
]}

Tanaka, Eiichi ^{[19
]}

Kawahito, Yutaka ^{[9
]}

Harigai, Masayoshi ^{[19
]}

机构：

[1] Kyoto Univ, Grad Sch Med, Dept Rheumatol & Clin Immunol, Kyoto, Japan

[2] Natl Def Med Coll, Dept Pharmacol, Tokorozawa, Saitama, Japan

[3] Japanese Red Cross Maebashi Hosp, Dept Rheumatol & Nephrol, Maebashi, Japan

[4] Kyorin Univ, Sch Med, Dept Emergency & Gen Med, Tokyo, Japan

[5] Univ Occupat & Environm Hlth, Dept Internal Med 1, Kitakyushu, Japan

[6] Hiroshima Univ Hosp, Dept Clin Immunol & Rheumatol, Hiroshima, Japan

[7] Univ Tokyo, Inst Med Sci, Dept Joint Surg, Res Hosp, Tokyo, Japan

[8] Kobe City Med Ctr Gen Hosp, Dept Rheumatol, Kobe, Japan

[9] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Inflammat & Immunol, Kyoto, Japan

[10] Keio Univ, Sch Med, Dept Internal Med, Div Rheumatol, Keio, Japan

[11] Kyoto Univ, Sch Publ Hlth, Grad Sch Med, Dept Prevent Serv, Kyoto, Japan

[12] Kyoto Univ, Fac Med, Kyoto, Japan

[13] Showa Univ, Div Rheumatol, Dept Med, Sch Med, Shinagawa, Japan

[14] Kyushu Univ, Dept Internal Med, Beppu Hosp, Beppu, Japan

[15] Otokoyama Hosp, Dept Orthopaed Surg & Rheumatol, Kyoto, Japan

[16] Univ Fukui Hosp, Dept Infect & Rheumatol, Fukui, Japan

[17] Yokohama City Univ, Dept Stem Cell & Immune Regulat, Grad Sch Med, Yokohama, Japan

[18] Nishida Hosp, Dept Rheumatol, Saiki, Oita, Japan

[19] Tokyo Womens Med Univ Sch Med, Dept Internal Med, Div Rheumatol, 8-1 Kawada Cho,Shinjuku Ku, Tokyo 1628666, Japan

[20] St Marianna Univ, Dept Internal Med, Div Rheumatol & Allergol, Sch Med, Kawasaki, Japan

[21] Saitama Med Univ, Fac Med, Dept Rheumatol & Appl Immunol, Saitama, Japan

[22] Kyoto Univ, Grad Sch Med, Dept Adv Med Rheumat Dis, Kyoto, Japan

[23] Yokohama City Univ, Dept Pediat, Grad Sch Med, Yokohama, Japan

[24] Osaka Metropolitan Univ, Dept Clin Immunol, Grad Sch Med, Osaka, Japan

[25] Showa Univ, Dept Internal Med, Div Nephrol, Fujigaoka Hosp, Yokohama, Japan

来源：

MODERN RHEUMATOLOGY | 2024年 / 34卷 / 06期

关键词：

Clinical practice guidelines; meta-analysis; ozoralizumab; rheumatoid arthritis; systematic review; INHIBITOR TOFACITINIB CP-690,550; MODIFYING ANTIRHEUMATIC DRUGS; ETANERCEPT REFERENCE PRODUCT; SELECTIVE JAK-1 INHIBITOR; PLACEBO-CONTROLLED TRIAL; INADEQUATE RESPONSE; DOUBLE-BLIND; PHASE-III; PARALLEL-GROUP; FILGOTINIB GLPG0634/GS-6034;

D O I：

10.1093/mr/roae049

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives: The aim of this article is to update evidence on the efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) and provide information to the taskforce for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis (RA). Methods: We searched various databases for randomised controlled trials on RA published until June 2022, with no language restriction. For each of the 15 clinical questions, two independent reviewers screened the articles, evaluated the core outcomes, and performed meta-analyses. Results: Subcutaneous injection of methotrexate (MTX) showed similar efficacy to oral MTX in MTX-naive RA patients. Ozoralizumab combined with MTX improved drug efficacy compared to the placebo in RA patients with inadequate response (IR) to conventional synthetic DMARD (sDMARD). Rituximab with and without concomitant csDMARDs showed similar efficacy to other biological DMARDs (bDMARDs) in bDMARD-IR RA patients. Combined Janus kinase inhibitors and MTX achieved similar clinical responses and equal safety during a 4-year period compared to tumour necrosis factor inhibitors in MTX-IR RA patients. Biosimilars showed efficacy equivalent to that of the original bDMARDs in csDMARD-IR and bDMARD-IR RA patients. Conclusions: This systematic review provides latest evidence for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for RA management.

引用

页码：1079 / 1094

页数：16

共 108 条

[1] Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54 [J].

Alten, Rieke ;

Batko, Bogdan ;

Hala, Tomas ;

Kameda, Hideto ;

Radominski, Sebastiao C. ;

Tseluyko, Vira ;

Babic, Goran ;

Cronenberger, Carol ;

Hackley, Sarah ;

Rehman, Muhammad ;

von Richter, Oliver ;

Zhang, Min ;

Cohen, Stanley .

RMD OPEN, 2019, 5 (01)

[2]

Apsangikar P., 2018, J ARTH RHEUMATOL RES, V1, P1

[3] A Prospective, Randomized, Double-blind, Comparative Clinical Study of Efficacy and Safety of a Biosimilar Adalimumab with Innovator Product in Patients with Active Rheumatoid Arthritis on a Stable Dose of Methotrexate [J].

Apsangikar, Prasad ;

Chaudhry, Sunil ;

Naik, Manoj ;

Deoghare, Shashank ;

Joseph, Jamila .

INDIAN JOURNAL OF RHEUMATOLOGY, 2018, 13 (02) :84-89

[4] A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study [J].

Bae, Sang-Cheol ;

Kim, Jinseok ;

Choe, Jung-Yoon ;

Park, Won ;

Lee, Sang-Heon ;

Park, Yong-Beom ;

Shim, Seung-Cheol ;

Lee, Shin-Seok ;

Sung, Yoon-Kyoung ;

Choi, Chan-Bum ;

Lee, So-Ra ;

Park, HanYu ;

Ahn, Yongho .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) :65-71

[5] Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study) [J].

Behrens, Frank ;

Koehm, Michaela ;

Rossmanith, Tanja ;

Alten, Rieke ;

Aringer, Martin ;

Backhaus, Marina ;

Burmester, Gerd R. ;

Feist, Eugen ;

Herrmann, Eva ;

Kellner, Herbert ;

Krueger, Klaus ;

Lehn, Annette ;

Muller-Ladner, Ulf ;

Rubbert-Roth, Andrea ;

Tony, Hans-Peter ;

Wassenberg, Siegfried ;

Burkhardt, Harald .

RHEUMATOLOGY, 2021, 60 (11) :5318-5328

[6] Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis [J].

Braun, J. ;

Kaestner, P. ;

Flaxenberg, P. ;

Waehrisch, J. ;

Hanke, P. ;

Demary, W. ;

von Hinueber, U. ;

Rockwitz, K. ;

Heitz, W. ;

Pichlmeier, U. ;

Guimbal-Schmolck, C. ;

Brandt, A. .

ARTHRITIS AND RHEUMATISM, 2008, 58 (01) :73-81

[7] Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT [J].

Brown, Sarah ;

Everett, Colin C. ;

Naraghi, Kamran ;

Davies, Claire ;

Dawkins, Bryony ;

Hulme, Claire ;

McCabe, Christopher ;

Pavitt, Sue ;

Emery, Paul ;

Sharples, Linda ;

Buch, Maya H. .

HEALTH TECHNOLOGY ASSESSMENT, 2018, 22 (34) :1-+

[8] Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis [J].

Buch, Maya H. ;

Smolen, Josef S. ;

Betteridge, Neil ;

Breedveld, Ferdinand C. ;

Burmester, Gerd ;

Doerner, Thomas ;

Ferraccioli, Gianfranco ;

Gottenberg, Jacques-Eric ;

Isaacs, John ;

Kvien, Tore K. ;

Mariette, Xavier ;

Martin-Mola, Emilio ;

Pavelka, Karel ;

Tak, Paul P. ;

van der Heijde, Desiree ;

van Vollenhoven, Ronald F. ;

Emery, Paul .

ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) :909-920

[9] A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis [J].

Burmester, Gerd ;

Chien, David ;

Chow, Vincent ;

Gessner, Melissa ;

Pan, Jean ;

Cohen, Stanley .

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (08) :1003-1014

[10] Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial [J].

Burmester, Gerd R. ;

Blanco, Ricardo ;

Charles-Schoeman, Christina ;

Wollenhaupt, Juergen ;

Zerbini, Cristiano ;

Benda, Birgitta ;

Gruben, David ;

Wallenstein, Gene ;

Krishnaswami, Sriram ;

Zwillich, Samuel H. ;

Koncz, Tamas ;

Soma, Koshika ;

Bradley, John ;

Mebus, Charles .

LANCET, 2013, 381 (9865) :451-460

← 1 2 3 4 5 6 7 8 9 10 →